Fracture - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 73 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fracture - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fracture - Pipeline Review, H2 2014', provides an overview of the Fracture's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fracture, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fracture and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fracture
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fracture and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fracture products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fracture pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fracture
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fracture pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Fracture Overview 8
Therapeutics Development 9
Pipeline Products for Fracture - Overview 9
Pipeline Products for Fracture - Comparative Analysis 10
Fracture - Therapeutics under Development by Companies 11
Fracture - Therapeutics under Investigation by Universities/Institutes 13
Fracture - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Fracture - Products under Development by Companies 17
Fracture - Products under Investigation by Universities/Institutes 18
Fracture - Companies Involved in Therapeutics Development 19
Eli Lilly and Company 19
Kuros Biosurgery AG 20
Novartis AG 21
Kolon Life Science, Inc. 22
TissueGene, Inc. 23
Radius Health, Inc. 24
Arcarios BV 25
Escape Therapeutics, Inc. 26
OrgaNext Research BV 27
Fracture - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
teriparatide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
abaloparatide - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
KUR-113 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
bimagrumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(nandrolone decanoate + cholecalciferol) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
rusalatide acetate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KLS-Bfr - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
OsteoStem - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
TG-B - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Stromal Cell Therapy For Fracture Repair - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Bone Morphogenetic Protein Modulators - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Fracture - Recent Pipeline Updates 58
Fracture - Dormant Projects 62
Fracture - Discontinued Products 63
Fracture - Product Development Milestones 64
Featured News & Press Releases 64
Mar 11, 2013: Merck Provides Update On Fosamax Product Liability Trial 64
Feb 11, 2013: UCB And Amgen Decide Not To Pursue Phase III Clinical Trial Program For CDP7851 64
Jan 07, 2013: Radius Provides Update On Pivotal Phase III Program For BA058-SC Injection 65
Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 65
Aug 07, 2012: Lilly Announces Study Results Regarding Postmenopausal Women With Back Pain Caused By Vertebral Fractures 66
Jan 24, 2011: Kuros Reports One Year Data From Phase IIb Study With KUR-111 67
Jun 02, 2010: Kuros Completes Patient Recruitment In A Phase IIB Trial Of KUR-113 In Patients With Tibial Shaft Fractures 68
Jun 01, 2010: Amgen Receives FDA Approval For Prolia For Treatment Of Postmenopausal Women With Osteoporosis At High Risk For Fracture 69
Mar 15, 2010: Kuros Meets Primary Efficacy Endpoint In Phase IIb Study With KUR-111 70
Jun 08, 2009: Kuros Completes Patient Recruitment In A Phase IIb Trial Of KUR-111 In Patients With Tibial Plateau Fractures 71
Appendix 72
Methodology 72
Coverage 72
Secondary Research 72
Primary Research 72
Expert Panel Validation 72
Contact Us 73
Disclaimer 73

List of Tables
Number of Products under Development for Fracture, H2 2014 9
Number of Products under Development for Fracture - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Fracture - Pipeline by Eli Lilly and Company, H2 2014 19
Fracture - Pipeline by Kuros Biosurgery AG, H2 2014 20
Fracture - Pipeline by Novartis AG, H2 2014 21
Fracture - Pipeline by Kolon Life Science, Inc., H2 2014 22
Fracture - Pipeline by TissueGene, Inc., H2 2014 23
Fracture - Pipeline by Radius Health, Inc., H2 2014 24
Fracture - Pipeline by Arcarios BV, H2 2014 25
Fracture - Pipeline by Escape Therapeutics, Inc., H2 2014 26
Fracture - Pipeline by OrgaNext Research BV, H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Assessment by Combination Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Fracture Therapeutics - Recent Pipeline Updates, H2 2014 58
Fracture - Dormant Projects, H2 2014 62
Fracture - Discontinued Products, H2 2014 63